Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2010 - 2022)
Jazz Pharmaceuticals (JAZZ) posted quarterly Non-Current Deffered Revenue of $116000.0 for Q3 2022, down 88.24% year-over-year from $986000.0 in Q3 2021, and down 49.78% quarter-over-quarter from $231000.0 in Q2 2022.
Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends
Jazz Pharmaceuticals' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $116000.0 for Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue fell 88.24% year-over-year to $116000.0; the TTM figure through Sep 2022 stood at $116000.0 (down 88.24% YoY), while the FY2021 annual figure was $463000.0, down 80.0% from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $116000.0, down from $231000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $13.6 million in Q1 2018, with the low at $116000.0 in Q3 2022.
- The 5-year median for Non-Current Deffered Revenue is $3.6 million (2020), against an average of $4.8 million.
- The sharpest annual moves came in 2019 and 2022: Non-Current Deffered Revenue plunged 38.41% in 2019, then slumped 88.24% in 2022.
- Jazz Pharmaceuticals' Non-Current Deffered Revenue stood at $9.6 million in 2018, then tumbled by 49.26% to $4.9 million in 2019, then tumbled by 52.38% to $2.3 million in 2020, then tumbled by 80.0% to $463000.0 in 2021, then tumbled by 74.95% to $116000.0 in 2022.
- Business Quant data shows JAZZ's Non-Current Deffered Revenue at $116000.0 in Q3 2022, $231000.0 in Q2 2022, and $347000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 116,000.00 |
| Jun 30, 2022 | 231,000.00 |
| Mar 31, 2022 | 347,000.00 |
| Dec 31, 2021 | 463,000.00 |
| Sep 30, 2021 | 986,000.00 |
| Jun 30, 2021 | 1.51 Mn |
| Mar 31, 2021 | 1.85 Mn |
| Dec 31, 2020 | 2.32 Mn |
| Sep 30, 2020 | 2.95 Mn |
| Jun 30, 2020 | 3.59 Mn |
| Mar 31, 2020 | 4.23 Mn |
| Dec 31, 2019 | 4.86 Mn |
| Sep 30, 2019 | 6.04 Mn |
| Jun 30, 2019 | 7.22 Mn |
| Mar 31, 2019 | 8.40 Mn |
| Dec 31, 2018 | 9.58 Mn |
| Sep 30, 2018 | 10.93 Mn |
| Jun 30, 2018 | 12.29 Mn |
| Mar 31, 2018 | 13.64 Mn |
| Dec 31, 2017 | 16.12 Mn |